Christopher Dinsmore Kronos Bio, Inc. (KRON) insider trading activity

Christopher Dinsmore is Chief Scientific Officer of Kronos Bio, Inc.. Currently has a direct ownership of 260,969 shares of KRON, which is worth approximately $300,114. The most recent transaction as insider was on Jan 04, 2024, when has been sold 7,366 shares (Common Stock) at a price of $1.18 per share, resulting in proceeds of $8,691. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 261K

0% 3M change

6.25% 12M change

Total Value Held $300,114

Christopher Dinsmore Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 04 2024	SELL Open market or private sale	$8,691 $1.18 p/Share	7,366 Reduced 2.75%	260,969 Common Stock
Dec 12 2023	SELL Open market or private sale	$13,041 $1.3 p/Share	10,032 Reduced 3.6%	268,335 Common Stock
Jul 06 2023	SELL Open market or private sale	$11,609 $1.75 p/Share	6,634 Reduced 2.33%	278,367 Common Stock
Feb 24 2023	SELL Open market or private sale	$10,946 $1.74 p/Share	6,291 Reduced 2.16%	285,001 Common Stock
Feb 15 2023	BUY Grant, award, or other acquisition	-	119,882 Added 29.16%	291,292 Common Stock
Dec 12 2022	SELL Open market or private sale	$16,539 $1.81 p/Share	9,138 Reduced 5.31%	162,936 Common Stock
Jul 25 2022	BUY Grant, award, or other acquisition	-	43,550 Added 20.2%	172,074 Common Stock

Feb 15 2022	BUY Grant, award, or other acquisition	-	43,550 Added 25.31%	128,524 Common Stock
Dec 13 2021	SELL Open market or private sale	$143,350 $12.59 p/Share	11,386 Reduced 11.82%	84,974 Common Stock
Oct 04 2021	SELL Open market or private sale	$191,223 $20.81 p/Share	9,189 Reduced 8.71%	96,360 Common Stock
Oct 04 2021	BUY Exercise of conversion of derivative security	$30,048 $3.27 p/Share	9,189 Added 8.01%	105,549 Common Stock
Sep 07 2021	SELL Open market or private sale	$201,331 $21.91 p/Share	9,189 Reduced 8.71%	96,360 Common Stock
Sep 07 2021	BUY Exercise of conversion of derivative security	$30,048 $3.27 p/Share	9,189 Added 8.01%	105,549 Common Stock
Aug 02 2021	SELL Open market or private sale	$189,202 $20.59 p/Share	9,189 Reduced 8.71%	96,360 Common Stock
Aug 02 2021	BUY Exercise of conversion of derivative security	$30,048 $3.27 p/Share	9,189 Added 8.01%	105,549 Common Stock
Dec 09 2020	BUY Grant, award, or other acquisition	-	91,110 Added 48.6%	96,360 Common Stock
Oct 14 2020	BUY Open market or private purchase	$99,750 $19.0 p/Share	5,250 Added 50.0%	5,250 Common Stock

Also insider at

THRD

Third Harmonic Bio, Inc. Healthcare

Chief Scientific Officer